Cleveland Clinic Florida's Cancer Research staff is dedicated to providing patients innovative therapies through clinical research trials which include new targeted agents and therapies. Cancer specialists from The Maroone Cancer's Departments of Hematology and Oncology serve as principal investigators for the trials, working closely with the research staff and collaborating with the world-renowned Taussig Cancer Institute at Cleveland Clinic in Ohio. Cleveland Clinic Florida also participates in many clinical trials with the National Cancer Institute.

For more information about our clinical trials, please contact:
Abel Rodriguez, Clinical Research Supervisor
Phone: 954.487.2258

Areas of Cancer Clinical Trials

Brain Cancer

A Randomized Phase III Trial Of Memantine And Whole-Brain Radiotherapy With Or Without Hippocampal Avoidance In Patients With Brain Metastases

Breast Cancer

NSABP B-51 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

SWOG S1416 - Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

A Phase IB/II Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-Dm1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use Of Adjuvant Endocrine Therapy +/- One Year Of Everolimus In Patients With High-Risk, Hormone Receptor-Positive And Her2/Neu Negative Breast Cancer

A Randomized Phase III Trial Of Endocrine Therapy Plus Entinostat/Placebo In Patients With Hormone Receptor-Positive Advanced Breast Cancer

NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Molecular Mechanisms Involved in Cancer Predisposition

  • Cleveland Clinic Study Number: IRB 8458
  • Principal Investigator: Charis Eng, MD


Endoesophageal Brachytherapy for Patients with Esophageal Cancer: A Balloon Repositioning, Multichannel Radiation Applicator for Optimizing Treatment Delivery


NRG-GU003 - A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy - Coport

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Head & Neck Cancer

Please check back for upcoming trials.


Please check back for upcoming trials.

Lung Cancer

MUSC 1516 / Prot# 102323 - A Phase IB/II Study of Nivolumab in Combination with ALT-803 in Patients with Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Adjuvant Lung Cancer Enrichment Market Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Randomized Phase III Study Of Nivolumab After Surgical Resection And Adjuvant Chemotherapy In Non-Small Cell Lung Cancers - Adjuvant Nivolumab In Resected Lung Cancers (Anvil)

Prostate Cancer

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Solid Tumor Cancer

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors